Agreement Between Roche and Tekmira to Advance RNAi Product Candidates
Taskin Ahmed
Abstract
Tekmira Pharmaceuticals and Roche announced a product development agreement to advance Roche’s first two RNAi product candidates into human clinical testing. Both RNAi product candidates are to be based on Tekmira’s SNALP technology.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.